Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 4/2011

Open Access 01-12-2011 | Research

Angiogenesis Markers Quantification in Breast Cancer and Their Correlation with Clinicopathological Prognostic Variables

Authors: Jan Rykala, Karolina Przybylowska, Ireneusz Majsterek, Grazyna Pasz-Walczak, Andrzej Sygut, Adam Dziki, Julia Kruk-Jeromin

Published in: Pathology & Oncology Research | Issue 4/2011

Login to get access

Abstract

Tumoural angiogenesis is essential for the growth and spread of breast cancer cells. Therefore the aim of this study was to assess the diagnostic performance of angiogenesis markers in tumours and there reflecting levels in serum of breast cancer patients. Angiogenin, Ang2, fibroblast growth factor basic, intercellular adhesion molecule (ICAM)-1, keratinocyte growth factor (KGF), platelet-derived growth factor-BB, and VEGF-A were measured using a FASTQuant angiogenic growth factor multiplex protein assay. We observed that breast cancer tumours exhibited high levels of PDGF-BB, bFGF and VEGF, and extremely high levels of TIMP-1 and Ang-2, whereas in serum we found significantly higher levels of Ang-2, PDGF-BB, bFGF, ICAM-1 and VEGF in patients with breast cancer compared to the benign breast diseases patients. Moreover, some of these angiogenesis markers evaluated in tumour and serum of breast cancer patients exhibited association with standard clinical parameters, ER status as well as MVD of tumours. Angiogenesis markers play important roles in tumour growth, invasion and metastasis. Our results suggest that analysis of angiogenesis markers in tumour and serum of breast cancer patients using multiplex protein assay can improve diagnosis and prognosis in this diseases.
Literature
1.
Baeriswyl V, Christofori G (2009) The angiogenic switch in carcinogenesis. Semin Cancer Biol 19(5):329–337PubMedCrossRef
2.
Fujita Y, Abe R, Shimizu H (2008) Clinical approaches toward tumor angiogenesis: past, present and future. Curr Pharm Des 14(36):3820–3834PubMedCrossRef
3.
Poon RT, Fan ST, Wong J (2001) Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19(4):1207–1225PubMed
4.
Uzzan B, Nicolas P, Cucherat M, Perret GY (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64(9):2941–2945PubMedCrossRef
5.
Ozalp S, Yalcin OT, Acikalin M, Tanir HM, Oner U, Akkoyunlu A (2003) Microvessel density (MVD) as a prognosticator in endometrial carcinoma. Eur J Gynaecol Oncol 24(3–4):305–308PubMed
6.
Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R (2002) Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 5(2):123–127PubMedCrossRef
7.
Liang JT, Huang KC, Jeng YM, Lee PH, Lai HS, Hsu HC (2004) Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer. Br J Surg 91(3):355–361PubMedCrossRef
8.
Szarvas T, Jäger T, Droste F, Becker M, Kovalszky I, Romics I, Ergün S, Rübben H (2009) Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathol Oncol Res 15(2):193–201PubMedCrossRef
9.
Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E (2006) Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 16(5):405–411PubMedCrossRef
10.
Balacescu O, Neagoe I, Balacescu L, Crisan N, Feciche B, Tudoran O, Coman I, Irimie A (2008) Angiogenesis serum protein quantification for prostate. Pathology Curr Urol 2:181–187CrossRef
11.
Balsari A, Maier JA, Colnaghi MI, Ménard S (1999) Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma. Lab Invest 79(7):897–902PubMed
12.
Zhao J, Yan F, Ju H, Tang J, Qin J (2004) Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett 204(1):87–95PubMedCrossRef
13.
Duranyildiz D, Camlica H, Soydinc HO, Derin D, Yasasever V (2009) Serum levels of angiogenic factors in early breast cancer remain close to normal. Breast 18(1):26–29PubMedCrossRef
14.
Weidner N, Semple JP, Welch ER, Folkman J (1991) Tumor angiogenesis et metastasis—correlation in invasive breast carcinoma. N Engl J Med 324:1–8PubMedCrossRef
15.
Vermeulen PB, Gasparini G, Fox SB (1996) Quantification of angiogenesis in solid human tumors: an International Consensus on the methodology and criteria of evaluation. Eur J Cancer 32:2474–2484CrossRef
16.
Kranz A, Mattfeldt T, Waltenberger J (1999) Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 84(3):293–298PubMedCrossRef
17.
Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, Chung GG (2008) High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 39(12):1835–1843PubMedCrossRef
18.
Kawai H, Li H, Chun P, Avraham S, Avraham HK (2002) Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 21(50):7730–7739PubMedCrossRef
19.
Ali SH, O’Donnell AL, Balu D, Pohl MB, Seyler MJ, Mohamed S, Mousa S, Dandona P (2000) Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis. Cancer Res 60(24):7094–7098PubMed
20.
Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E (2005) Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 46(1):31–36PubMedCrossRef
21.
Guo P, Hu B, Gu W, Xu L, Wang D, Huang HJ, Cavenee WK, Cheng SY (2003) Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162(4):1083–1093PubMedCrossRef
22.
Zhu L, Loo WT, Cheng CW, Chow LW (2006) Possible predictive markers related to micro-metastasis in breast cancer patients. Oncol Rep 15(5):1217–1223PubMed
23.
Schweigerer L, Neufeld G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D (1987) Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 325(6101):257–259PubMedCrossRef
24.
Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA (2006) Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Arch 448(1):68–74PubMedCrossRef
25.
Shi YH, Bingle L, Gong LH, Wang YX, Corke KP, Fang WG (2007) Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells. Pathology 39(4):396–400PubMedCrossRef
26.
Sartippour MR, Zhang L, Lu M, Wang HJ, Brooks MN (2005) Nipple fluid basic fibroblast growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 14(12):2995–2998PubMedCrossRef
27.
Würtz SO, Schrohl AS, Mouridsen H, Brünner N (2008) TIMP-1 as a tumor marker in breast cancer–an update. Acta Oncol 47(4):580–590PubMedCrossRef
28.
Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298(1):29–32PubMedCrossRef
29.
Liu XW, Bernardo MM, Fridman R, Kim HR (2003) Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 278(41):40364–40372PubMedCrossRef
30.
Liu H, Chen B, Lilly B (2008) Fibroblasts potentiate blood vessel formation partially through secreted factor TIMP-1. Angiogenesis 11(3):223–234PubMedCrossRef
31.
O’Hanlon DM, Fitzsimons H, Lynch J, Tormey S, Malone C, Given HF (2002) Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer 38:2252–2257PubMedCrossRef
32.
Kostler WJ, Tomek S, Brodowicz T et al (2001) Soluble ICAM-1 in breast cancer: clinical significance and biological implications. Cancer Immunol Immunother 50:483–490PubMed
33.
Kawai Y, Kaidoh M, Yokoyama Y, Sano K, Ohhashi T (2009) Chemokine CCL2 facilitates ICAM-1-mediated interactions of cancer cells and lymphatic endothelial cells in sentinel lymph nodes. Cancer Sci 100(3):419–428PubMedCrossRef
34.
Tsutsui S, Inoue H, Yasuda K, Suzuki K, Takeuchi H, Nishizaki T, Higashi H, Era S, Mori M (2006) Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res Treat 98(3):261–266PubMedCrossRef
35.
Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, Augustin HG (2009) Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 15(4):1384–1392PubMedCrossRef
36.
Zhou YZ, Fang XQ, Li H, Diao YT, Yang YF, Zhao DL, Wu K, Li HQ (2007) Role of serum angiopoietin-2 level in screening for esophageal squamous cell cancer and its precursors. Chin Med J (Engl) 120(14):1216–1219
37.
A Randomized Phase III Trial of Paclitaxel With or Without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer: Eastern Cooperative Oncology Group trial E 2100. Abstract 7
Metadata
Title
Angiogenesis Markers Quantification in Breast Cancer and Their Correlation with Clinicopathological Prognostic Variables
Authors
Jan Rykala
Karolina Przybylowska
Ireneusz Majsterek
Grazyna Pasz-Walczak
Andrzej Sygut
Adam Dziki
Julia Kruk-Jeromin
Publication date
01-12-2011
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 4/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9387-6

Other articles of this Issue 4/2011

Pathology & Oncology Research 4/2011 Go to the issue

OriginalPaper

Ezrin Expression as a Prognostic Marker in Colorectal Adenocarcinoma

Research

High Frequency of Genes’ Promoter Methylation, but Lack of BRAF V600E Mutation among Iranian Colorectal Cancer Patients

Research

TWIST1 Promoter Methylation in Primary Colorectal Carcinoma

Research

Chemotherapy Response Analysis for Osteosarcom with Intra-arterial Chemotherapy by Subcutaneous Implantable Delivery System

Research

Lack of Prognostic Significance of Survivin in Pediatric Medulloblastoma

Research

Watchful Waiting and Active Surveillance Approach in Patients with Low Risk Localized Prostatic Cancer: An Experience of Out-Patients Clinic with 12-Year Follow-Up
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits